Partner Headlines - ALKS

  1. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  2. Alkermes Announces Completion Of Patient Enrollment In Phase ...

    Benzinga
  3. US Stock Futures Rise Ahead Of Economic Data

    Benzinga
  4. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For ...

    Benzinga
  5. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  6. Alkermes' drug passes trial

    IBD
  7. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  8. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  9. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  10. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  11. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  12. Benzinga's Volume Movers

    Benzinga
  13. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  14. Morning Market Movers

    Benzinga
  15. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  16. Benzinga's Top Initiations

    Benzinga
  17. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  18. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  19. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  20. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  21. Stocks End Short Week With Big Losses

    IBD
  22. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  23. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  24. Ireland Home To Several Fast Growing Health Care Names

    IBD
  25. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  26. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  27. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  28. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  29. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  30. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  31. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  32. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  33. Alkermes

    IBD
  34. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  35. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  36. Alkermes

    IBD
  37. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  38. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  39. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  40. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  41. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  42. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  43. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  44. Stocks Pare Early Losses, End With Modest Declines

    IBD
  45. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  46. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  47. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  48. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  49. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  50. Dow Leads Market Higher As Volume Swells

    IBD
  51. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  52. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  53. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  54. Stocks Tumble On Disappointing Earnings Reports

    IBD
  55. Why Cisco, Google And Apple All Became Big Winners

    IBD
  56. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  57. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
  58. Alkermes In Buying Range Above Cup-Base Entry

    IBD
  59. Alkermes Writes New Prescription For Growth

    IBD
  60. Lennar, Other Homebuilders Crush Profit Estimates

    IBD
  61. Health Care Sector Wrap

    FoxBusiness
  62. UPDATE: J.P. Morgan Lowers Alkermes' PT

    Benzinga
  63. UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for ...

    Benzinga
  64. Elan

    IBD
  65. Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary ...

    Benzinga
  66. Alkermes Announces a Secondary Offering of 13,900,000 Ordinary ...

    Benzinga
  67. Market Roundup

    Benzinga
  68. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  69. Alkermes Files Resale Shelf Registration in Connection with Elan ...

    Benzinga
  70. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  71. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  72. Alkermes Inc. (ALKS) Director and CEO, Alkermes plc Richard F ...

    GuruFocus
  73. Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon ...

    Benzinga
  74. Benzinga's M&A Chatter for Monday January 30, 2012

    Benzinga
  75. Benzinga's Top Pre-Market Gainers

    Benzinga
  76. UPDATE: FDA Approves BYDUREON, for Type 2 Diabetes

    Benzinga
  77. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  78. Benzinga's Volume Gainers

    Benzinga
  79. CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous ...

    Benzinga
  80. Feuerstein: Alkermes CEO says Bydureon Drug will be Approved ...

    Benzinga
  81. Top-Performing Fund Managers Tap Retail, Food Stocks

    IBD
  82. Positive Data Lifts Stocks in Early Trading

    MarketIntelligenceCenter
  83. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
Trading Center